Comparing of Acer Therapeutics Inc. (ACER) and Sutro Biopharma Inc. (NASDAQ:STRO)

We are contrasting Acer Therapeutics Inc. (NASDAQ:ACER) and Sutro Biopharma Inc. (NASDAQ:STRO) on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acer Therapeutics Inc. N/A 0.00 21.28M -2.01 0.00
Sutro Biopharma Inc. 38.42M 6.06 35.32M -2.21 0.00

Demonstrates Acer Therapeutics Inc. and Sutro Biopharma Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 has Acer Therapeutics Inc. and Sutro Biopharma Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acer Therapeutics Inc. 0.00% -62.9% -57.9%
Sutro Biopharma Inc. -91.93% 0% 0%

Liquidity

The Current Ratio of Acer Therapeutics Inc. is 22 while its Quick Ratio stands at 22. The Current Ratio of rival Sutro Biopharma Inc. is 3.5 and its Quick Ratio is has 3.5. Acer Therapeutics Inc. is better equipped to clear short and long-term obligations than Sutro Biopharma Inc.

Analyst Recommendations

The Recommendations and Ratings for Acer Therapeutics Inc. and Sutro Biopharma Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acer Therapeutics Inc. 0 0 1 3.00
Sutro Biopharma Inc. 0 0 0 0.00

The average price target of Acer Therapeutics Inc. is $40, with potential upside of 77.70%.

Institutional & Insider Ownership

Acer Therapeutics Inc. and Sutro Biopharma Inc. has shares held by institutional investors as follows: 59.3% and 75.3%. About 24.21% of Acer Therapeutics Inc.’s share are held by insiders. Comparatively, insiders own roughly 8.5% of Sutro Biopharma Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acer Therapeutics Inc. 1.7% -2.41% 1.19% -25.55% 37.99% 18.79%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year Acer Therapeutics Inc.’s stock price has bigger growth than Sutro Biopharma Inc.

Summary

On 6 of the 10 factors Acer Therapeutics Inc. beats Sutro Biopharma Inc.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.